CATALOGO DEI PRODOTTI DELLA RICERCA

MELISI, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.747
EU - Europa 7.089
AS - Asia 5.480
SA - Sud America 719
AF - Africa 150
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 5
Totale 21.207
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.602
RU - Federazione Russa 2.759
SG - Singapore 2.124
CN - Cina 1.795
GB - Regno Unito 1.251
IT - Italia 764
BR - Brasile 564
SE - Svezia 515
VN - Vietnam 487
HK - Hong Kong 465
DE - Germania 446
FR - Francia 367
IE - Irlanda 367
FI - Finlandia 259
KR - Corea 174
CA - Canada 84
UA - Ucraina 83
BD - Bangladesh 72
IN - India 67
NL - Olanda 60
AR - Argentina 56
JP - Giappone 48
TR - Turchia 43
MX - Messico 36
NG - Nigeria 36
ZA - Sudafrica 36
AT - Austria 35
PL - Polonia 33
ES - Italia 29
ID - Indonesia 29
IQ - Iraq 24
EC - Ecuador 22
BE - Belgio 21
SA - Arabia Saudita 20
VE - Venezuela 18
PY - Paraguay 17
TG - Togo 17
AU - Australia 16
CL - Cile 16
PK - Pakistan 16
BJ - Benin 15
CH - Svizzera 15
JO - Giordania 15
MA - Marocco 15
PH - Filippine 14
UZ - Uzbekistan 13
CO - Colombia 12
CZ - Repubblica Ceca 12
LT - Lituania 12
PT - Portogallo 11
IR - Iran 8
MY - Malesia 8
DZ - Algeria 7
PE - Perù 7
AE - Emirati Arabi Uniti 6
KE - Kenya 6
NP - Nepal 6
AL - Albania 5
AZ - Azerbaigian 5
KG - Kirghizistan 5
UY - Uruguay 5
BG - Bulgaria 4
BY - Bielorussia 4
EE - Estonia 4
EG - Egitto 4
EU - Europa 4
GR - Grecia 4
HU - Ungheria 4
KZ - Kazakistan 4
LK - Sri Lanka 4
NO - Norvegia 4
PA - Panama 4
QA - Qatar 4
RO - Romania 4
SN - Senegal 4
AM - Armenia 3
CR - Costa Rica 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
GE - Georgia 3
HN - Honduras 3
HR - Croazia 3
IL - Israele 3
JM - Giamaica 3
LB - Libano 3
BO - Bolivia 2
CI - Costa d'Avorio 2
KH - Cambogia 2
LV - Lettonia 2
OM - Oman 2
PS - Palestinian Territory 2
RS - Serbia 2
TH - Thailandia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
BT - Bhutan 1
Totale 21.185
Salva come PNG Salva come JPEG
Città #
Singapore 1.103
Southend 1.033
Ashburn 1.008
Moscow 933
Chandler 841
San Jose 765
Dallas 634
Jacksonville 490
Hong Kong 462
Woodbridge 400
Dublin 365
Verona 309
The Dalles 278
Beijing 272
Ann Arbor 268
Ho Chi Minh City 178
Jinan 162
Council Bluffs 156
Houston 139
Lawrence 132
New York 132
Princeton 132
Los Angeles 127
Wilmington 126
Munich 122
Shenyang 97
Hanoi 94
Nanjing 89
Helsinki 82
Tianjin 78
Buffalo 73
Hebei 66
São Paulo 60
Redondo Beach 54
Changsha 53
Columbus 53
Zhengzhou 47
Santa Clara 46
Milan 45
Sindelfingen 45
Haikou 44
Frankfurt am Main 42
Turku 42
Orem 41
Taiyuan 39
Tokyo 39
Hangzhou 38
Guangzhou 36
London 36
Redwood City 35
Abuja 34
Nanchang 31
Ningbo 31
Taizhou 31
Rome 28
Toronto 28
Montreal 27
Atlanta 26
Johannesburg 26
Seattle 26
Warsaw 26
Fuzhou 25
Washington 25
Da Nang 23
Nuremberg 23
Rio de Janeiro 23
San Francisco 23
Amsterdam 22
Boardman 22
Chicago 22
Denver 22
Redmond 22
Kent 21
Brooklyn 20
Brussels 20
Dong Ket 20
Jiaxing 20
Jakarta 19
Phoenix 19
Vienna 18
Boston 17
Lomé 17
Norwalk 17
Barnet 16
Bologna 16
Brasília 16
Belo Horizonte 15
Cotonou 15
Haiphong 15
Seoul 15
Stockholm 15
Amman 14
Chennai 14
Dongguan 14
Lanzhou 13
Zurich 13
Ankara 12
Baghdad 12
Campinas 12
Mexico City 12
Totale 12.954
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 316
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 291
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 260
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 254
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 250
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 235
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma 232
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 219
NF-κB as a target for pancreatic cancer therapy. 214
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 204
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial 203
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma 201
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer 200
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 195
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 193
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 192
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 191
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 191
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 189
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 188
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 185
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 185
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 184
Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells 184
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 183
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer 183
Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. 183
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer 179
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 179
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype 178
The development of PARP as a successful target for cancer therapy 177
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 176
Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results 175
Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer 175
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data 174
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 173
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 173
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 172
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib 171
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 170
Pancreatic Cancer: between bench and bedside. 167
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 165
CT texture analysis of ductal adenocarcinoma downstaged after chemotherapy 164
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance 163
EMT and Treatment Resistance in Pancreatic Cancer 163
Histogram analysis of magnetic resonance images: evaluation of intra-tumoral heterogeneity and correlation with pathological findings in solid pancreatic tumors. 163
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 162
ESGAR 2018 Book of Abstracts 159
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 156
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 155
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 155
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 155
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion 155
Angiogenesis: A target for cancer therapy. 154
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 154
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 154
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity 154
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 153
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 152
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. 150
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 150
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma 148
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer 146
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy 143
Toll-Like Receptor 9 Agonists for Cancer Therapy 143
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 142
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 138
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial 137
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 136
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 136
HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies 135
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 134
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma 134
Clinical Response to Futibatinib in Patients with High-Level FGFR2-Amplified Advanced Gastric Cancer: Two Case Reports 133
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 131
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 128
Rare secondary tumors of the pancreas 128
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 128
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers 126
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer 126
Injectable Thermogelling Nanostructured Ink as Simultaneous Optical and Magnetic Resonance Imaging Contrast Agent for Image-Guided Surgery 125
YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer 124
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 124
The curious case of Gαs gain-of-function in neoplasia 123
The Multifaceted Role of TGF-β in Gastrointestinal Tumors 123
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus 122
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 121
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 121
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells 121
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough 121
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) 119
Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy 119
Permissive State of EMT: The Role of Immune Cell Compartment 119
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 118
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 118
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC) 118
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells 118
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 117
p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells 116
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinib ('Iressa') cooperatively inhibits growth and angiogenic factor expression in breast and prostate carcinoma cells. 116
Totale 16.255
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.622
article - articoli 64.962
book - libri 0
conference - conferenze 8.917
curatela - curatele 0
other - altro 482
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.261
Totale 151.244
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202179 0 0 0 0 0 0 0 0 0 0 0 79
2021/20221.221 87 433 13 167 15 15 9 62 38 22 68 292
2022/20232.311 180 234 221 357 209 553 28 138 293 23 49 26
2023/20241.331 43 101 94 123 164 183 116 166 15 71 198 57
2024/20253.233 167 191 110 510 138 99 177 160 491 200 311 679
2025/20269.194 686 430 685 1.424 2.274 625 894 487 733 568 173 215
Totale 21.403